<DOC>
	<DOCNO>NCT00778583</DOCNO>
	<brief_summary>An open label , randomise , two-treatment , four-period , two-sequence , single-dose , crossover , fully replicate bioavailability study Nitrofurantoin formulation compare Nitrofurantoin 100 mg capsule Ranbaxy Laboratories Macrobid 100 mg capsule healthy , adult , human subject feed condition</brief_summary>
	<brief_title>Bioequivalence Study Nitrofurantoin 100 mg Capsules Under Fed Conditions</brief_title>
	<detailed_description>This open-label , randomize , single-dose , four period fully replicate crossover , relative bioavailability study perform 40 healthy adult male . A total 35 complete clinical phase study .</detailed_description>
	<mesh_term>Nitrofurantoin</mesh_term>
	<criteria>Be age range 1845 year . Be neither overweight underweight his/her height per Life insurance Corporation India height/weight chart nonmedical case . Have voluntarily give write informed consent participate study . Be normal health determine medical history physical examination subject perform within 14 day prior commencement study . If female : Of childbearing potential , practice acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence ; Is postmenopausal least I year ; Is surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) . History allergy nitrofurantoin and/or relate drug . Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination . Evidence haemolysis ( glucose6phosphotase ) deficiency . Presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . Female volunteer demonstrate positive pregnancy test . Female volunteer currently breastfeed . Presence value significantly different normal reference range ( define Appendix 5 ) and/or judge clinically significant haemoglobin , total white blood cell count , differential WBC count platelet count . Positive urinary screen test drug abuse ( opiates cannabinoids ) Presence value significantly different normal reference range ( define Appendix 5 ) and/or judge clinically significant serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . Clinically abnormal chemical microscopic examination udne define presence RI3C , WBC ( &gt; 4/HPF ) , epithelial cell ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . Clinically abnormal ECG Chest Xray . History serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological haematological disease , diabetes , glaucoma gout . History psychiatric illness may impair ability provide write informed consent . Regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . History drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unify.equivalent half pint beer ! glass wine 1 measure spirit ) difficulty abstain duration study period . Use enzyme modi~ing drug within 30 day prior Day 1 study . Participation clinical trial within 12 week precede Day ! study . A haemoglobin concentration le 7 % low limit reference range e.g . 13 gm % reference range 1418 gm screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequivalence Nitrofurantoin capsule</keyword>
</DOC>